Bococizumab

Cat. No.:	HY-P99187
CAS No.:	1407495-02-6
Target:	Ser/Thr Protease
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia[1][2].
IC_{50} & Target	PCSK9[1]
In Vivo	Bococizumab (0-100 mg/kg, i.v.) decreases maternal and fetal cholesterol and does not affect rat embryo-fetal development [2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Pregnant Sprague-Dawley (SD) rats[1]
Dosage:	0, 10, 30, and 100 mg/kg
Administration:	Intravenous injection (i.v.)
Result:	Decreased in fetal cholesterol levels. Showed well tolerance and no effects on ovarian or uterine parameters.

REFERENCES

[1]. Koutaro Yokote, et al. Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive - Results From a Randomized, Placebo-Controlled, Dose-Ranging Study. Circ J. 2017 Sep 25;81(10):1496-1505.

[2]. Sarah N Campion, et al. Decreased maternal and fetal cholesterol following maternal bococizumab (anti-PCSK9 monoclonal antibody) administration does not affect rat embryo-fetal development. Regul Toxicol Pharmacol. 2015 Nov;73(2):562-70.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA